Iterum Therapeutics to Present Data at IDWeek 2022
17 oct. 2022 17h19 HE
|
Iterum Therapeutics plc
Analysis of data from Phase 3 studies in uUTI and cUTI to assess the relevance of a positive urine culture in patients with no clinical symptoms after being treated for a UTINew data on the efficacy...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
19 sept. 2022 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 09h15 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
01 sept. 2022 16h15 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
16 août 2022 21h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
12 août 2022 07h00 HE
|
Iterum Therapeutics plc
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq:...
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
11 juil. 2022 07h30 HE
|
Iterum Therapeutics plc
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN,...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2022 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 juin 2022 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2022 Financial Results
13 mai 2022 07h00 HE
|
Iterum Therapeutics plc
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum...